According to reports, Durvalumab’s overall response rate (ORR) in the treatment of HNSCC is 9.2% [358], with progression-free survival rates of 20% for all HNSCC patients, reaching 25% in PD-L1-positive patients [359]. Here, CD274 is linked to head and neck squamous cell carcinoma.